ONFO
Onfolio Holdings, Inc.
Internet Content & Information
Market Cap$6M
5Y Perf.-39.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ONFO vs ITRM
Revenue, margins, valuation, and 5-year total return — side by side.
ITRM
Iterum Therapeutics plc
Biotechnology
Market Cap$2M
5Y Perf.-98.8%
ONFO vs ITRM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ONFO | ITRM |
|---|---|---|
| Industry | Internet Content & Information | Biotechnology |
| Market Cap | $6M | $2M |
| Revenue (TTM) | $11M | $390K |
| Net Income (TTM) | $-2M | $-27M |
| Gross Margin | 60.3% | -171.3% |
| Operating Margin | -19.7% | -52.0% |
| Total Debt | $3M | $46M |
| Cash & Equiv. | $477K | $24M |
ONFO vs ITRM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ONFO
ITRM
| Stock | Aug 22 | May 26 | Return |
|---|---|---|---|
| Onfolio Holdings, I… (ONFO) | 100 | 60.2 | -39.8% |
| Iterum Therapeutics… (ITRM) | 100 | 1.2 | -98.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ONFO vs ITRM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ONFO leads in 6 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
ONFO
Onfolio Holdings, Inc.
The Income Pick
ONFO carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 4 yrs, beta 1.42, yield 5.6%
- Rev growth 50.0%, EPS growth 75.0%, 3Y rev CAGR 63.2%
- -53.3% 10Y total return vs ITRM's -100.0%
Best for: income & stability and growth exposure
ITRM
Iterum Therapeutics plc
The Specific-Use Pick
In this particular matchup, ITRM is outpaced on most metrics by others in the set.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ONFO | 50.0% revenue growth vs ITRM's 14.8% |
| Quality / Margins | ONFO | -17.2% margin vs ITRM's -69.1% |
| Stability / Safety | ONFO | Beta 1.42 vs ITRM's 1.49 |
| Dividends | ONFO | 5.6% yield; 4-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | ONFO | +5.7% vs ITRM's -96.6% |
| Efficiency (ROA) | ONFO | -23.3% ROA vs ITRM's -74.8%, ROIC -38.2% vs -117.8% |
ONFO vs ITRM — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLONFOLAGGINGITRM
ITRMIterum Therapeutics p…
0leads
ONFOOnfolio Holdings, Inc.
5leads
6 Total Categories
CATEGORYLEADERvs ITRMMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ONFO4/5
Valuation MetricsMultiples, price ratios, and targets
ONFO1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ONFO7/7
Total Returns1Y, 3Y, 5Y total returns with dividends
ONFO6/6
Risk & VolatilityBeta, volatility, and downside exposure
ONFO2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ONFO leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
ONFO is the larger business by revenue, generating $11M annually — 28.8x ITRM's $390,000. ONFO is the more profitable business, keeping -17.2% of every revenue dollar as net income compared to ITRM's -69.1%.
| Metric | ONFOOnfolio Holdings,… | ITRMIterum Therapeuti… |
|---|---|---|
| RevenueTrailing 12 months | $11M | $390,000 |
| EBITDAEarnings before interest/tax | -$1M | -$19M |
| Net IncomeAfter-tax profit | -$2M | -$27M |
| Free Cash FlowCash after capex | -$1M | -$20M |
| Gross MarginGross profit ÷ Revenue | +60.3% | -171.3% |
| Operating MarginEBIT ÷ Revenue | -19.7% | -52.0% |
| Net MarginNet income ÷ Revenue | -17.2% | -69.1% |
| FCF MarginFCF ÷ Revenue | -9.0% | -51.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +36.3% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -45.5% | +33.3% |
ONFO leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
ONFO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ONFOOnfolio Holdings,… | ITRMIterum Therapeuti… |
|---|---|---|
| Market CapShares × price | $6M | $2M |
| Enterprise ValueMkt cap + debt − cash | $8M | $23M |
| Trailing P/EPrice ÷ TTM EPS | -2.73x | -0.02x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.73x | — |
| Price / BookPrice ÷ Book value/share | 1.32x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
ONFO leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
ONFO leads this category, winning 7 of 7 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), ONFO scores 2/9 vs ITRM's 1/9, reflecting mixed financial health.
| Metric | ONFOOnfolio Holdings,… | ITRMIterum Therapeuti… |
|---|---|---|
| ROE (TTM)Return on equity | -51.7% | — |
| ROA (TTM)Return on assets | -23.3% | -74.8% |
| ROICReturn on invested capital | -38.2% | -117.8% |
| ROCEReturn on capital employed | -51.5% | -94.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 1 |
| Debt / EquityFinancial leverage | 0.60x | — |
| Net DebtTotal debt minus cash | $2M | $21M |
| Cash & Equiv.Liquid assets | $476,874 | $24M |
| Total DebtShort + long-term debt | $3M | $46M |
| Interest CoverageEBIT ÷ Interest expense | -6.65x | -10.61x |
ONFO leads this category, winning 7 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
ONFO leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ONFO five years ago would be worth $4,667 today (with dividends reinvested), compared to $19 for ITRM. Over the past 12 months, ONFO leads with a +5.7% total return vs ITRM's -96.6%. The 3-year compound annual growth rate (CAGR) favors ONFO at -1.3% vs ITRM's -69.7% — a key indicator of consistent wealth creation.
| Metric | ONFOOnfolio Holdings,… | ITRMIterum Therapeuti… |
|---|---|---|
| YTD ReturnYear-to-date | +49.3% | -90.2% |
| 1-Year ReturnPast 12 months | +5.7% | -96.6% |
| 3-Year ReturnCumulative with dividends | -3.9% | -97.2% |
| 5-Year ReturnCumulative with dividends | -53.3% | -99.8% |
| 10-Year ReturnCumulative with dividends | -53.3% | -100.0% |
| CAGR (3Y)Annualised 3-year return | -1.3% | -69.7% |
ONFO leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
ONFO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ONFO is the less volatile stock with a 1.42 beta — it tends to amplify market swings less than ITRM's 1.49 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ONFO currently trades 45.2% from its 52-week high vs ITRM's 2.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ONFOOnfolio Holdings,… | ITRMIterum Therapeuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.42x | 1.49x |
| 52-Week HighHighest price in past year | $2.48 | $1.28 |
| 52-Week LowLowest price in past year | $0.45 | $0.03 |
| % of 52W HighCurrent price vs 52-week peak | +45.2% | +2.4% |
| RSI (14)Momentum oscillator 0–100 | 54.1 | 29.6 |
| Avg Volume (50D)Average daily shares traded | 5.9M | 36.8M |
ONFO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
ONFO is the only dividend payer here at 5.61% yield — a key consideration for income-focused portfolios.
| Metric | ONFOOnfolio Holdings,… | ITRMIterum Therapeuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | +5.6% | — |
| Dividend StreakConsecutive years of raises | 4 | — |
| Dividend / ShareAnnual DPS | $0.06 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ONFO leads in 5 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics.
Best OverallOnfolio Holdings, Inc. (ONFO)Leads 5 of 6 categories
Loading custom metrics...
ONFO vs ITRM: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — ONFO or ITRM?
Over the past 5 years, Onfolio Holdings, Inc.
(ONFO) delivered a total return of -53. 3%, compared to -99. 8% for Iterum Therapeutics plc (ITRM). Over 10 years, the gap is even starker: ONFO returned -53. 3% versus ITRM's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — ONFO or ITRM?
By beta (market sensitivity over 5 years), Onfolio Holdings, Inc.
(ONFO) is the lower-risk stock at 1. 42β versus Iterum Therapeutics plc's 1. 49β — meaning ITRM is approximately 5% more volatile than ONFO relative to the S&P 500.
03Which is growing faster — ONFO or ITRM?
On earnings-per-share growth, the picture is similar: Onfolio Holdings, Inc.
grew EPS 75. 0% year-over-year, compared to 57. 4% for Iterum Therapeutics plc. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — ONFO or ITRM?
Onfolio Holdings, Inc.
(ONFO) is the more profitable company, earning -22. 5% net margin versus -69. 1% for Iterum Therapeutics plc — meaning it keeps -22. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ONFO leads at -31. 9% versus -52. 0% for ITRM. At the gross margin level — before operating expenses — ONFO leads at 57. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — ONFO or ITRM?
In this comparison, ONFO (5.
6% yield) pays a dividend. ITRM does not pay a meaningful dividend and should not be held primarily for income.
06Is ONFO or ITRM better for a retirement portfolio?
For long-horizon retirement investors, Onfolio Holdings, Inc.
(ONFO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (5. 6% yield). Both have compounded well over 10 years (ONFO: -53. 3%, ITRM: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between ONFO and ITRM?
These companies operate in different sectors (ONFO (Communication Services) and ITRM (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ONFO is a small-cap high-growth stock; ITRM is a small-cap quality compounder stock. ONFO pays a dividend while ITRM does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
- Sector: Communication Services
- Market Cap > $100B
- Revenue Growth > 18%
- Gross Margin > 36%
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.